Ferenc Darvas, founder and president of board at NanGenex, said: “This is a major milestone in the development of a new class of innovative Nanodrugs that provide fundamental improvements and clinically meaningful benefits over the original drug formulations. NanoForm Cardiovascular Therapeutics has acquired all rights to the two proprietary NanoActive formulations. It is in advanced discussions with strategic investors and pharmaceutical partners to bring these breakthrough products to the market.”
Gabor Heltovics, CEO of NanGenex, said: “We are very excited about the great results we have generated with the two NanoActive formulations. It has once again showed the significant benefit that can be achieved with the NanoActive technology. The unique nanostructured particle formation will be applicable for many established drugs with limited solubility and or permeability to transform them into instantaneously redispersable form with increased solubility.
“Moreover, the virtual high throughput nanoparticle drug delivery technology enables us to design and produce nanostructured pharmaceutical macromolecules (eg.; polypeptides, polynucleotides) and highly stable nanostructured particles for prolonged release injectable formulations.”